
Immunex Corporation was founded in 1981 by Stuart L. Squyres. It was initially focused on developing treatments for autoimmune diseases.
The company's early success came with the development of the first recombinant human interferon gamma, which was used to treat chronic granulomatous disease. This marked a significant milestone in the field of immunology.
Immunex Corporation was later acquired by Amgen in 2002, expanding its reach and capabilities in the biotech industry.
Company History
Immunex was founded in 1981 by Stuart L. Levy, a microbiologist and professor at Tufts University.
The company's first product was a yeast-derived recombinant human interleukin-2, which was used to treat certain types of cancer.
Immunex's early success was driven by its innovative approach to biotechnology and its commitment to developing new treatments for serious diseases.
The company's first FDA approval was for the treatment of hairy cell leukemia in 1992.
Immunex was acquired by Amgen in 2002 for $16 billion.
Under Amgen's ownership, Immunex continued to develop and commercialize new treatments, including alemtuzumab for chronic lymphocytic leukemia.
Product Introductions
Immunex introduced Leukine (GM-CSF) in the United States in March 1991, which received FDA approval to treat bone marrow transplant patients. This was a major milestone for the company, with shares skyrocketing to a record high of $59.
The company's sales team was organized to market Leukine to oncology specialists, and Immunex continued to invest in new drugs, including Pixie 321, a synthetic molecule that combined the properties of Leukine and Interleukin 3.
In 1992, Amgen introduced a similar product, Neupogen, which was approved for the much larger chemotherapy market, ultimately stealing more than 90 percent of the market for Leukine.
Introduces Leukine
In March 1991, Immunex won FDA approval to market Leukine in the United States to treat bone marrow transplant patients.
This approval was a major milestone for Immunex, with its shares rocketing to a record high of $59 following the announcement.
Immunex initiated an aggressive marketing program to sell Leukine, employing a 50-member sales team to market the product to oncology specialists.
Despite the initial excitement, Leukine ultimately failed to live up to expectations, with revenues topping out at less than $23 million in 1993.
The main culprit behind this disappointing performance was Amgen's Neupogen, a similar product that received approval for the much larger chemotherapy market in 1992.
This meant that Neupogen's shipments skyrocketed to $290 million in 1993, leaving Leukine in its wake.
Immunex had hoped to offset its losses with increased sales of Leukine, but unfortunately, that was not the case.
Enbrel
Enbrel was first approved by the FDA in 1998 for the treatment of moderate to severe rheumatoid arthritis.
Enbrel is a biologic medication that works by targeting a specific protein in the body that causes inflammation.
It was also approved for the treatment of psoriatic arthritis in 2002.
Enbrel has been shown to significantly reduce symptoms of rheumatoid arthritis, such as joint pain and swelling.
In 2004, Enbrel was approved for the treatment of ankylosing spondylitis, a type of arthritis that affects the spine.
Regulatory Approvals
In March 1991, Immunex received FDA approval to market Leukine (GM-CSF) in the United States to treat bone marrow transplant patients.
This approval was a major milestone for the company, as it allowed Immunex to sell Leukine through a 50-member sales team to oncology specialists.
The FDA approval was a significant boost to Immunex's stock, with shares rocketing to a record high of $59 following the announcement.
However, the company faced stiff competition from Amgen, which received approval for its similar drug Neupogen in 1992.
Acquisitions and Mergers
Immunex was bought out by American Cyanamid in June 1993, creating a new publicly traded company still known as Immunex. This merger failed to produce the desired results, and the stock price slipped to $30 before dropping to less than $15 per share in 1994.
The company's stock price fluctuated significantly, but it eventually recovered. In 1994, the stock price was around $15 per share, a significant drop from its previous value.
Immunex was later acquired by Amgen Inc. in a $16 billion deal in 2002, creating a $72-billion biotechnology behemoth. Amgen will pay around $30 per share for Immunex, representing a 17 percent premium to Immunex's closing price on Friday.
Bought Out by American Cyanamid
In June 1993, Immunex was bought out by American Cyanamid.
The merger created a new, publicly traded company still known as Immunex, headquartered in Seattle. This company combined Immunex's powerful research operations with Lederle Oncology's established marketing network.
Lederle Oncology had about a half dozen proprietary products in its drug portfolio, which seemed like a natural complement to Immunex's operations. Unfortunately, Lederle's products did not sell as well as expected.
The stock price of the new company slipped to $30 before dropping to less than $15 per share in 1994. This decline was likely due to the combined issues of poor sales for Lederle's products and less-than-stellar gains with Leukine.
Amgen Cleared to Buy
Amgen Inc. won U.S. antitrust clearance to complete its $9.6-billion purchase of Immunex Corp.
The companies agreed to grant patent licenses to address FTC concerns that the acquisition would hurt competition and lead to higher drug prices.
Amgen will receive Immunex's Enbrel, a rheumatoid arthritis drug, and market it along with its own arthritis medication, Kineret.
Regeneron Pharmaceuticals Inc. received a license from Amgen and Immunex to use a patent for developing a rheumatoid arthritis drug.
The companies also agreed to grant another patent license to develop a drug that blocks TNF, or tumor necrosis factor.
Amgen will pay 0.44 share of Amgen plus $4.50 in cash for each share of Immunex.
Immunex shares rose 5 cents to $19.55 on Nasdaq after the FTC clearance.
Products and Substances
Immunex products and substances are diverse and have various applications.
Antirheumatic Agents are part of the Immunex offerings, which help alleviate rheumatic symptoms.
Immunoglobulin G is another substance used in Immunex products, playing a crucial role in immune system functions.
Receptors, Tumor Necrosis Factor, are also involved in Immunex products, which help regulate inflammation.
Recombinant Fusion Proteins are used in Immunex products, combining different proteins to achieve specific effects.
Etanercept is a notable product from Immunex, used to treat autoimmune disorders by blocking tumor necrosis factor.
Neutrophil Regeneration Factors

Neutrophil Regeneration Factors are used to treat neutropenia, a condition where the production of certain white blood cells is suppressed, often as a result of chemotherapy. This is a common issue for cancer patients undergoing treatment.
These factors stimulate the production of neutrophils, a type of white blood cell, allowing patients to maintain a robust immune system while continuing with their chemotherapy regimens. Annual U.S. sales of these products total approximately $1.2 billion.
The market for Neutrophil Regeneration Factors is highly concentrated, with only two companies, Amgen and Immunex, having products approved for sale in the United States. Amgen's Neupogen is the leading product in this market, with 2001 sales of approximately $1.05 billion in the United States.
Entering this market requires significant resources and time, with clinical development and FDA approval taking 6 to 10 years and costing over $200 million. The FDA must approve all phases of development, including extensive preclinical and clinical work.
To succeed in this market, a company needs clinical trial expertise, patent rights, commercial scale product manufacturing expertise and capacity, and regulatory approvals. This is a challenging and costly process, making it difficult for new companies to enter the market.
TNF Inhibitors
TNF Inhibitors are a class of medications that can help with inflammation and autoimmune diseases. They work by blocking the action of tumor necrosis factor, a substance in the body that promotes inflammation.
Etanercept is an example of a TNF inhibitor, specifically a recombinant fusion protein. It's designed to mimic the natural protein that blocks tumor necrosis factor.
Immunoglobulin G is another substance that can be involved in the body's response to TNF inhibitors. However, its actions are not directly related to TNF inhibition.
Receptors, Tumor Necrosis Factor, are the targets of TNF inhibitors like Etanercept. By blocking these receptors, TNF inhibitors can reduce inflammation and disease symptoms.
Antirheumatic Agents, a broader category of medications, may include TNF inhibitors like Etanercept. These agents are designed to reduce inflammation and relieve symptoms of autoimmune diseases.
Financial Performance
Immunex set records for sales, profit, and cash flow in 2000, a testament to the company's growing success in the biotechnology industry.
Product sales for 2001 reached $960 million, a 16-percent increase over the previous year's sales.
The company's stock split in 2000 was a three-for-one split, which likely made its stock more attractive to investors.
Immunex's financial performance was so impressive that it was added to the S&P 500, a prestigious index of top-performing companies.
Its inclusion in Fortune magazine's lists of the "Fastest Growing Company in America" and one of the "100 Best Companies to Work for in America" further solidified its reputation as a leader in the industry.
Amgen $16B Deal
Amgen's $16B Deal was a game-changer in the biotechnology industry.
The deal was made between Amgen and Immunex, with Amgen paying about $30 per share for Immunex, representing a 17 percent premium to Immunex's closing price on Friday.
This merger created a $72-billion biotechnology behemoth, giving Amgen added research strength and financial muscle to buy late-stage development drugs from rival firms.

Amgen will gain Immunex's drug Enbrel, a leading rheumatoid arthritis treatment, as well as several potential treatments for asthma and various forms of cancer.
Under the terms of the agreement, each Immunex common share will be exchanged for 0.44 shares of Amgen common stock and cash of $4.50.
The acquisition will make Amgen a leader in the more than $10-billion potential inflammation market in biologics.
Amgen expects to post pro forma 2002 revenues of about $5.5 billion and net income above $1.5 billion.
The company estimated cost synergies of more than $200 million in 2003 and more than $250 million in 2004.
The merger is expected to generate significant benefits for hundreds of thousands of patients around the world.
As a result of the merger, annual sales of Immunex's rheumatoid arthritis treatment Enbrel will likely reach $3 billion or more.
Sets Records for Sales, Profit, and Cash Flow
Immunex set records for product sales, profit, and cash flow in 2000. This was a significant achievement for the company, demonstrating its growth and success in the biotechnology industry.

Product sales for 2001 reached $960 million, a 16-percent increase over the previous year's sales. This increase shows that the company was able to expand its customer base and increase revenue.
New records were set for sales of Enbrel, with plans to expand manufacturing capacity to keep up with growing demand. This indicates that the company's products were in high demand and needed to be produced in larger quantities.
For the first time, sales of Leukine exceeded $100 million. This is a notable milestone for the company, demonstrating the success of its product.
Immunex was added to the S&P 500, a prestigious stock market index. This recognition is a testament to the company's financial performance and stability.
In 2000, Immunex effected a three-for-one stock split. This move likely made the company's stock more attractive to investors and helped to increase its market value.
The company's financial performance was also recognized by Fortune magazine, which named Immunex as one of the "100 Best Companies to Work for in America."
Amgen
Amgen is a biotechnology company that's made some big moves in the industry. Amgen is the world's largest biotechnology company.
The company has a significant presence in the market, with a potential inflammation market in biologics worth over $10 billion. Amgen is looking to capitalize on this market with its acquisition of Immunex.
Amgen's chairman and CEO, Kevin Sharer, sees the acquisition as a strategic move that will benefit shareholders, employees, and partners of both companies. He expects the deal to generate significant benefits for hundreds of thousands of patients around the world.
As a result of the merger, Amgen will gain access to Immunex's drug Enbrel, a leading rheumatoid arthritis treatment. This acquisition will make Amgen a leader in the inflammation market in biologics.
Amgen will pay about $30 per share for Immunex, which represents a 17 percent premium to Immunex's closing price on Friday. The company will also pay a nearly 23 percent premium to Immunex's closing price on Wednesday, before word of the possible deal leaked out.
The acquisition will create a $72-billion biotechnology behemoth with added research strength and the financial muscle to buy late-stage development drugs from rival firms.
Frequently Asked Questions
Who is the manufacturer of Immunex?
Immunex was acquired by Amgen, a leading biotechnology company, in 2001. Amgen manufactured Immunex's products, including those produced at the company's lab and factory in Bothell, Washington.
Where is Immunex located?
Immunex is located at 51 University St, Seattle, WA 98101, US. This address is also listed on MapQuest.
Featured Images: pexels.com
